TCA
TXG icon

Trifecta Capital Advisors’s 10x Genomics TXG Stock Holding History

Trifecta Capital Advisors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.46K Hold
210
– – ﹤0.01% 247
2025
Q4 		$3.43K Sell
210
-17,130
-99% -$259K ﹤0.01% 249
2025
Q3 		$203K Sell
17,340
-11,860
-41% -$155K 0.03% 106
2025
Q2 		$338K Buy
+29,200
New +$266K 0.06% 82

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Trifecta Capital Advisors's TXG Position: Q1 2026 in Review

Trifecta Capital Advisors held its 10x Genomics (TXG) position steady in Q1 2026 at 210 shares worth $4.46K. The position accounts for ﹤0.01% of the portfolio, ranked #247.

Trifecta Capital Advisors first reported a position in TXG in Q2 2025 and has held it in 4 quarters since. The position peaked at $338K in Q2 2025. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Trifecta Capital Advisors held 210 shares of 10x Genomics worth $4.46K as of Q1 2026.
  • Trifecta Capital Advisors left its 10x Genomics share count unchanged in Q1 2026.
  • 10x Genomics made up ﹤0.01% of Trifecta Capital Advisors's portfolio in Q1 2026, its #247 holding.
  • Trifecta Capital Advisors first reported a position in 10x Genomics in Q2 2025 and has held it in 4 quarters since.
  • Trifecta Capital Advisors's 10x Genomics position peaked at $338K in Q2 2025.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Trifecta Capital Advisors's 13F filing for Q1 2026, filed 1 May 2026.